Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Overall serious adverse events · people who smoke
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
It is very uncertain whether long‐term red cell transfusion changes serious adverse events as a result of sickle cell‐related… compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
It is very uncertain whether long‐term red cell transfusion changes serious adverse events as a result of sickle cell‐related… compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
Long‐term red cell transfusion may leads to lower serious adverse events as a result of sickle cell‐related… compared with no transfusion (low certainty).
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Serious adverse events/death: long‐term outcomes ‐ not reported · rehabilitation (long‐term outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Long‐term serious adverse events · patients with rheumatoid arthritis
1 finding from 1 review
Intervention not reported
Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious cardiovascular adverse events ‐ bradycardia 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
1 finding from 1 review